Cargando…
The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
INTRODUCTION: Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease, but no drug therapies have been approved to date. While glucagon-like peptide-1 (GLP-1) analogues may help in the management, the existing evidence remains conflicting. AIM: This meta-analysis aims t...
Autores principales: | Malik, Adnan, Amjad, Waseem, Inayat, Faisal, Nadeem, Mahum, Weissman, Simcha, Malik, Muhammad Imran, Jajja, Ans Ahmad, Khan, Ahmad, Tabibian, James H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050979/ https://www.ncbi.nlm.nih.gov/pubmed/37007754 http://dx.doi.org/10.5114/pg.2022.112775 |
Ejemplares similares
-
Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis
por: Malik, Adnan, et al.
Publicado: (2022) -
Endoscopic Submucosal Tunnel Dissection as a Novel Therapeutic
Technique in Patients With Barrett’s Esophagus
por: Inayat, Faisal, et al.
Publicado: (2020) -
Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis–Related Cirrhosis With Liraglutide
por: Yuen, Christina, et al.
Publicado: (2023) -
Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis()
por: Weissman, Simcha, et al.
Publicado: (2021) -
Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)